Our top pick for
Precipio Inc is a diagnostics & research business based in the US. Precipio shares (PRPO) are listed on the NASDAQ and all prices are listed in US Dollars. Precipio employs 54 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.56|
|52-week range||$1.72 - $5.75|
|50-day moving average||$2.94|
|200-day moving average||$3.15|
|Wall St. target price||$7.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.45|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||0.39%|
|1 month (2021-09-17)||-17.68%|
|3 months (2021-07-16)||-14.95%|
|6 months (2021-04-16)||38.38%|
|1 year (2020-10-16)||10.34%|
|2 years (2019-10-17)||6.22%|
|3 years (2018-10-17)||653.61%|
|5 years (2016-10-17)||1,180.00%|
|Revenue TTM||$7.7 million|
|Gross profit TTM||$1.2 million|
|Return on assets TTM||-21.29%|
|Return on equity TTM||-48.25%|
|Market capitalisation||$58.1 million|
TTM: trailing 12 months
There are currently 300,983 Precipio shares held short by investors – that's known as Precipio's "short interest". This figure is 40.6% down from 506,933 last month.
There are a few different ways that this level of interest in shorting Precipio shares can be evaluated.
Precipio's "short interest ratio" (SIR) is the quantity of Precipio shares currently shorted divided by the average quantity of Precipio shares traded daily (recently around 320194.68085106). Precipio's SIR currently stands at 0.94. In other words for every 100,000 Precipio shares traded daily on the market, roughly 940 shares are currently held short.
However Precipio's short interest can also be evaluated against the total number of Precipio shares, or, against the total number of tradable Precipio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precipio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Precipio shares in existence, roughly 10 shares are currently held short) or 0.0137% of the tradable shares (for every 100,000 tradable Precipio shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Precipio.
Find out more about how you can short Precipio stock.
We're not expecting Precipio to pay a dividend over the next 12 months.
Precipio's shares were split on a 1:15 basis on 28 April 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Precipio shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Precipio shares which in turn could have impacted Precipio's share price.
Over the last 12 months, Precipio's shares have ranged in value from as little as $1.72 up to $5.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precipio's is 2.6425. This would suggest that Precipio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Precipio, Inc. , a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.